FDA-cleared profile

AIR Recon DL

Ge Medical Systems, LLC · MRI · FDA-cleared (510(k))

Authorized purpose: AIR Recon DL adds a deep-learning phase-correction and reconstruction option to supported GE 1.5T, 3T, and 7T MR workflows for all labeled anatomies and ages to reduce noise or ringing and support image quality or scan-time choices.

Clinical role
Applies the supported deep-learning reconstruction and phase-correction option to MR acquisitions before professional image review.
Images and patients
MRI · Multi-region
Key limitation
Keep in mind: Applicability depends on the supported GE scanner, field strength, sequence, enabled option key, acquisition protocol, and image quality; image-quality evidence does not establish patient outcomes or diagnostic superiority.

Overview status: Source-reviewed overview

Report a correction

Evaluation pilot

Before you shortlist

Exact FDA record: K252379 · Agent source review · . This is not clinician review or local acceptance.

Within this record's scope

  • Consider for optional integrated reconstruction and phase-correction functions on supported GE MR systems and labeled acquisitions.

Limits to check

  • Scanner, sequence and option-key scope must match the installed system. Image-quality findings do not establish patient outcomes or guaranteed cash savings.

Questions for the vendor and your team

  1. Does the offer include the required scanner-software version, reconstruction options and activation keys?
  2. Which local sequences will the team test for artifacts, image quality and quantitative output before accepting the configuration?

These questions are prompts for evaluation, not claims that licensing, compatibility, performance or price has been confirmed.

Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Image processing · source-reviewed 2026-11-12

Agent source review of original FDA labeling; not clinician sign-off or local workflow qualification.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: AIR Recon DL adds a deep-learning phase-correction and reconstruction option to supported GE 1.5T, 3T, and 7T MR workflows for all labeled anatomies and ages to reduce noise or ringing and support image quality or scan-time choices.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Multi-region Input: MR acquisition data from supported GE 1.5T, 3T, or 7T systems and labeled sequences, including multi-intermediate sequences such as diffusion-weighted imaging where supported.
  • Who uses it?Intended users: Prescription use (21 CFR 801 Subpart D); the FDA document does not name a specific user group.
  • What does the software produce?Output: Reconstructed MR images with reduced noise and ringing (truncation artifacts), which can be used to reduce scan time and improve image quality.
  • What is its most important limitation?Key limitation: Applicability depends on the supported GE scanner, field strength, sequence, enabled option key, acquisition protocol, and image quality; image-quality evidence does not establish patient outcomes or diagnostic superiority.

Clinical takeaway. Clinical role: AIR Recon DL adds a deep-learning phase-correction and reconstruction option to supported GE 1.5T, 3T, and 7T MR workflows for all labeled anatomies and ages to reduce noise or ringing and support image quality or scan-time choices.

Evidence takeaway. Evidence from the reviewed source record: K252379 FDA material describes bench and clinical image-quality evaluation including six volunteers across 1.5T and 3T systems and 34 de-identified datasets spanning breast, liver, brain, spine, and pelvis; all reported datasets were of diagnostic quality and no patient-outcome claim is made.

Evidence context: questions, not a score

Agent transcription of regulatory evidence context, not independent validation, clinical acceptance or a product recommendation. Separate studies and outcomes are not a leaderboard.

K252379 · agent source review 2026-11-12 · exact submission

Existing study anchor: K252379 FDA performance package for AIR Recon DL. Tested version label: AIR Recon DL with phase correction cleared in K252379.

What was tested?

Phase-corrected MR reconstruction in phantom/quantitative tests, plus a separate radiologist clinical image-quality assessment.

Source section: 510(k) summary, Summary of Nonclinical Testing and Clinical Image Quality Study

On which cases and versions?

The clinical image-quality assessment used 34 datasets: breast 6, liver 5, brain 5, spine 3 and pelvis 15. Four brain diffusion scans refer only to low-contrast insert testing, not the entire evidence package.

Source section: 510(k) summary, Summary of Nonclinical Testing and Clinical Image Quality Study

What changed?

The summary reports improved phase/signal estimates and quantitative diffusion measures relative to the predicate, and favorable radiologist image-quality assessment. These are reconstruction and image-quality results, not a disease-detection trial.

Source section: 510(k) summary, Summary of Nonclinical Testing and Clinical Image Quality Study

What does this not establish?

A favorable 34-dataset image-quality review does not establish patient outcomes, all-protocol performance, routine throughput or independent validation. Conference/publication citations in the submission are not newly admitted clinical studies here.

Source section: 510(k) summary, Summary of Nonclinical Testing and Clinical Image Quality Study

Study design, population and missing context
evidence Role
Phantom/quantitative reconstruction tests and a separate retrospective clinical image-quality assessment.

technical validation · 510(k) summary, Summary of Nonclinical Testing and Clinical Image Quality Study

design
Quantitative tests compare phase-corrected reconstruction against the predicate; a US board-certified radiologist assessed 34 previously acquired de-identified datasets.

technical validation · 510(k) summary, Summary of Nonclinical Testing and Clinical Image Quality Study

setting
Not established: The reviewed regulatory summary does not establish this field for this study context.
training Population
Not established: The reviewed regulatory summary does not establish this field for this study context.
evaluation Population
Four brain diffusion scans were used for low-contrast insert testing, not the full clinical package. Separate image-quality assessment: 34 datasets across breast, liver, brain, spine and pelvis.

technical validation · 510(k) summary, Summary of Nonclinical Testing and Clinical Image Quality Study

reference Standard
Predicate reconstruction/conventional images for quantitative tests; radiologist image-quality assessment for the separate 34-dataset review.

technical validation · 510(k) summary, Summary of Nonclinical Testing and Clinical Image Quality Study

comparator
AIR Recon DL with Phase Correction versus predicate reconstruction in quantitative tests. Clinical image-quality review is a separate assessment.

technical validation · 510(k) summary, Summary of Nonclinical Testing and Clinical Image Quality Study

sites
Not established: The reviewed regulatory summary does not establish this field for this study context.
scanner Protocol
Brain diffusion quantitative tests include 1.5 T data and specified b-values; clinical quality datasets include multiple anatomies. Do not infer every licensed system/protocol was tested in each subtest.

technical validation · 510(k) summary, Summary of Nonclinical Testing and Clinical Image Quality Study

sample Composition
Clinical image-quality review: 34 datasets, breast 6, liver 5, brain 5, spine 3, pelvis 15. Four brain scans belong to the low-contrast insert subtest only.

technical validation · 510(k) summary, Summary of Nonclinical Testing and Clinical Image Quality Study

sponsor Involvement
GE HealthCare prepared the performance package. The summary refers to a US board-certified radiologist for image-quality assessment but does not establish investigator independence.

regulatory summary · 510(k) summary, Summary of Nonclinical Testing and Clinical Image Quality Study

Public-label constraints

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Exact FDA submission K252379 · agent source review 2026-11-09 · AIR Recon DL with phase correction cleared in K252379

Label age limits

Patients of all ages, explicitly stated in the labeling.

Documented care setting

Not established: No explicit constraint transcribed from the reviewed labeling sections. Unknown does not mean unrestricted.

Modality and protocol

Deep-learning reconstruction on GE HealthCare 1.5 T, 3.0 T and 7.0 T MR systems.

Labeled anatomy

All anatomies, explicitly stated in the labeling.

Acquisition constraints

GE HealthCare 1.5 T, 3.0 T or 7.0 T MR systems. Contrast agents may be used depending on anatomy. Phase-correction enhancement is activated by an additional software option key.

Exclusions and human review

Not established: No explicit constraint transcribed from the reviewed labeling sections. Unknown does not mean unrestricted.

Purpose
AIR Recon DL adds a deep-learning phase-correction and reconstruction option to supported GE 1.5T, 3T, and 7T MR workflows for all labeled anatomies and ages to reduce noise or ringing and support image quality or scan-time choices.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Applies the supported deep-learning reconstruction and phase-correction option to MR acquisitions before professional image review.
  • Exact FDA submission
  • Checked 2026-09-04

Prior source-backed dossier value: Image reconstruction and phase correction after MR data acquisition and before diagnostic interpretation.

Required input
MR acquisition data from supported GE 1.5T, 3T, or 7T systems and labeled sequences, including multi-intermediate sequences such as diffusion-weighted imaging where supported.
  • Exact FDA submission
  • Checked 2026-09-04

Prior source-backed dossier value: Compatible raw MR acquisition data, including multiple intermediate images for supported diffusion workflows.

Output and clinician action
Reconstructed MR images with reduced noise and ringing (truncation artifacts), which can be used to reduce scan time and improve image quality.
  • Exact FDA submission
  • Checked 2026-11-12

Indications for Use wording. The FDA document does not name who reviews the output, so the earlier "for radiologist review" clause was removed. Prior source-backed dossier value: Reconstructed MR images with reduced noise or ringing and phase-corrected combined images.

Intended users
Prescription use (21 CFR 801 Subpart D); the FDA document does not name a specific user group.
  • Exact FDA submission
  • Checked 2026-11-12

The Indications for Use form checks only "Prescription Use (Part 21 CFR 801 Subpart D)" and names no user group. The earlier radiologist, MRI-technologist, and qualified-professional value was not supported by this source and was removed. The U.S. board-certified radiologist in the clinical image-quality study is a study reader, not an intended-user statement. Agent source review, not clinician sign-off.

Limitations
Applicability depends on the supported GE scanner, field strength, sequence, enabled option key, acquisition protocol, and image quality; image-quality evidence does not establish patient outcomes or diagnostic superiority.
  • Exact FDA submission
  • Checked 2026-09-04

Prior source-backed dossier value: Acquisition-time savings and image-quality effects depend on sequence, anatomy, field strength, protocol, and workflow. The feature does not itself establish diagnostic accuracy or shorter total room time.

Evidence summary
K252379 FDA material describes bench and clinical image-quality evaluation including six volunteers across 1.5T and 3T systems and 34 de-identified datasets spanning breast, liver, brain, spine, and pelvis; all reported datasets were of diagnostic quality and no patient-outcome claim is made.
  • Exact FDA submission
  • Checked 2026-09-04

Prior source-backed dossier value: K252379 reports phantom and in-vivo brain diffusion testing. Four brain scans with synthetic low-contrast inserts showed significantly improved contrast-to-noise with phase correction while retaining contrast, and ADC testing reduced low-SNR bias. Independent product-family workflow literature should not be treated as exact-version validation.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K252379 FDA material describes bench and clinical image-quality evaluation including six volunteers across 1.5T and 3T systems and 34 de-identified datasets spanning breast, liver, brain, spine, and pelvis; all reported datasets were of diagnostic quality and no patient-outcome claim is made.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04

Prior source-backed dossier value: K252379 reports phantom and in-vivo brain diffusion testing. Four brain scans with synthetic low-contrast inserts showed significantly improved contrast-to-noise with phase correction while retaining contrast, and ADC testing reduced low-SNR bias. Independent product-family workflow literature should not be treated as exact-version validation.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below. Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below. Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Low-contrast insert brain scans

4 scans

  • EndpointSynthetic-object contrast and contrast-to-noise comparison
  • PopulationAIR Recon DL
  • Tested versionAIR Recon DL with phase correction cleared in K252379

K252379 FDA performance package for AIR Recon DL

  • DesignManufacturer package of separate tests: phantom testing of the DLPC and PC-ARDL models; in-vivo bench testing of ADC accuracy and low-contrast detectability against the predicate; a volunteer ADC repeatability study against product reconstruction; and a clinical image-quality assessment by one U.S. board-certified radiologist
  • PopulationDiffusion-weighted brain images acquired at 1.5T with b-values of 50, 400, 800, and 1200 s/mm2 (count not stated); 4 diffusion-weighted brain scans with synthetic low-contrast inserts (field strength not stated); 6 volunteers (2 at 1.5T, 4 at 3T) scanned in brain, spine, abdomen, pelvis, and breast; 34 previously acquired de-identified datasets (breast 6, liver 5, brain 5, spine 3, pelvis 15)
  • Scopeexact submission
  • Tested versionAIR Recon DL with phase correction cleared in K252379
  • IndependenceSponsor or vendor study

K252379

Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary. The subtests use different samples, so no single package sample size is reported; the 4-scan count applies only to low-contrast insert testing.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K252379 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals. Prior source-backed dossier value: The 2026-09-02 openFDA device-recall snapshot contained no record matched to K252379 by exact submission identifier.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

Prior source-backed dossier value: No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the device within the applicable imaging or surgical service line and verify payer, site-of-service, and coding assumptions independently.

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: MR acquisition data from supported GE 1.5T, 3T, or 7T systems and labeled sequences, including multi-intermediate sequences such as diffusion-weighted imaging where supported.

    Scope: Exact FDA submission. Prior source-backed dossier value: Compatible raw MR acquisition data, including multiple intermediate images for supported diffusion workflows.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K252379: AIR Recon DL

  2. Routing

    Source context, not route validation: The FDA material describes an integrated GE MR software option key and reconstruction path within supported GE MR systems and sequences.

    Scope: Exact FDA submission. This is the interface boundary described in the exact FDA decision material; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing. Prior source-backed dossier value: Embedded reconstruction on compatible GE MR platforms; validate DICOM appearance, scaling, quantitative maps, protocol transfer, and downstream analysis.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K252379: AIR Recon DL · GE HealthCare AIR Recon DL · Impact of Deep Learning Image Reconstruction Methods on MRI Throughput

  3. AI processing

    Source context, not route validation: The FDA material describes software integrated into supported GE MR systems and enabled by an option key; current scanner configuration, service, security, and upgrade boundaries remain unverified.

    Scope: Exact FDA submission. This is the release-level boundary described in the exact FDA decision material; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence. Prior source-backed dossier value: Licensed reconstruction software on compatible GE 1.5T, 3T, or 7T MR system configurations.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) decision material K252379: AIR Recon DL · GE HealthCare AIR Recon DL · Impact of Deep Learning Image Reconstruction Methods on MRI Throughput

  4. Returned objects

    Source context, not route validation: Reconstructed MR images with reduced noise and ringing (truncation artifacts), which can be used to reduce scan time and improve image quality.

    Scope: Exact FDA submission. Indications for Use wording. The FDA document does not name who reviews the output, so the earlier "for radiologist review" clause was removed. Prior source-backed dossier value: Reconstructed MR images with reduced noise or ringing and phase-corrected combined images.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-11-12 · FDA 510(k) decision material K252379: AIR Recon DL

  5. Viewer/worklist/report

    Unresolved route: Reconstructed MR images with reduced noise and ringing (truncation artifacts), which can be used to reduce scan time and improve image quality.

    Scope: Exact FDA submission. Indications for Use wording. The FDA document does not name who reviews the output, so the earlier "for radiologist review" clause was removed. Prior source-backed dossier value: Reconstructed MR images with reduced noise or ringing and phase-corrected combined images.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-11-12 · FDA 510(k) decision material K252379: AIR Recon DL

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA material describes software integrated into supported GE MR systems and enabled by an option key; current scanner configuration, service, security, and upgrade boundaries remain unverified.
  • Exact FDA submission
  • Checked 2026-09-04

This is the release-level boundary described in the exact FDA decision material; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence. Prior source-backed dossier value: Licensed reconstruction software on compatible GE 1.5T, 3T, or 7T MR system configurations.

Integration
The FDA material describes an integrated GE MR software option key and reconstruction path within supported GE MR systems and sequences.
  • Exact FDA submission
  • Checked 2026-09-04

This is the interface boundary described in the exact FDA decision material; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing. Prior source-backed dossier value: Embedded reconstruction on compatible GE MR platforms; validate DICOM appearance, scaling, quantitative maps, protocol transfer, and downstream analysis.

Security
GE HealthCare's Product Security Portal is described as a credentialed global portal giving customers security updates, vulnerability status and required actions for GE HealthCare products potentially impacted by critical vulnerabilities, plus historical patch views; GE HealthCare references its Cybersecurity Risk Management System and publishes a Coordinated Vulnerability Disclosure Statement for reporting vulnerabilities in GE HealthCare products.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: GE HealthCare's own Privacy Shield page on gehealthcare.com names GE Medical Systems LLC as a US entity of the GEHC group. Corporate program statement; portal content is credentialed; exact-release scope is not established.

Monitoring
Monitor K252379 by exact hardware, software, model, algorithm version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: Applicability depends on the supported GE scanner, field strength, sequence, enabled option key, acquisition protocol, and image quality; image-quality evidence does not establish patient outcomes or diagnostic superiority.
  • Exact FDA submission
  • Checked 2026-09-04

Buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service. Prior source-backed dossier value: Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: Acquisition-time savings and image-quality effects depend on sequence, anatomy, field strength, protocol, and workflow. The feature does not itself establish diagnostic accuracy or shorter total room time.

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K252379 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Embedded reconstruction on compatible GE MR platforms; validate DICOM appearance, scaling, quantitative maps, protocol transfer, and downstream analysis.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Acquisition-time savings and image-quality effects depend on sequence, anatomy, field strength, protocol, and workflow. The feature does not itself establish diagnostic accuracy or shorter total room time.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: Acquisition-time savings and image-quality effects depend on sequence, anatomy, field strength, protocol, and workflow. The feature does not itself establish diagnostic accuracy or shorter total room time.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Deployment boundary

The FDA material describes software integrated into supported GE MR systems and enabled by an option key; current scanner configuration, service, security, and upgrade boundaries remain unverified.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K252379
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-12-23
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Documented product family

Related FDA records

These links identify a sourced product-family relationship. They do not transfer evidence, metrics, clearance scope, compatibility, pricing, or availability between submissions.

AIR Recon DL

Open the documented family

A partial mapping of two reviewed FDA submissions. Evidence, compatible inputs, licensing and availability remain specific to each record.

The K252379 summary explicitly describes a modification of AIR Recon DL K213717. The phase-correction enhancement needs an additional software option key. Scanner-system records are not included.

Mapped FDA decisions, earliest first

Latest mapped does not mean latest sold or installed. Choose an exact FDA record before comparing.

  1. Related FDA recordAIR Recon DL (K213717)

    AIR Recon DL in K213717

    FDA decision: 2022-06-08 · record reviewed 2026-11-09
  2. This FDA recordAIR Recon DL (K252379)

    AIR Recon DL with Phase Correction in K252379

    Latest mapped FDA decisionFDA decision: 2025-12-23 · record reviewed 2026-11-09

Documented names and scope

  • AIR Recon DL · K213717. Name for this exact FDA record, not an alias for every commercial configuration. Name source
  • AIR Recon DL with Phase Correction · K252379. Name for this exact FDA record, not an alias for every commercial configuration. Name source

AIR Recon DL

MR reconstruction to reduce noise and ringing artifacts. Applies to K213717, K252379. This describes the mapped function only; feature parity and a shared license are not established.

Availability evidence, separate from FDA decisions

  • not established

    Current availability of an exact FDA-submission configuration is not established. Ask the supplier for the offered release and licensed modules.

Latest FDA decision among these records
K252379 · 2025-12-23. Latest mapped decision only. Not automatically the latest sold or installed version, and not a supersession claim.
Latest documented release
Current commercial release or exact offered configuration is not established by this partial mapping.
Current commercial availability
Current commercial release or exact offered configuration is not established by this partial mapping.

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
32Fields reviewed
11Source classes checked
12Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads

Screened 12 PubMed and one ClinicalTrials.gov record. AIR Recon DL records do not link their tested release to the K252379 phase-correction configuration, while the remaining records are generic reconstruction studies; all 13 were quarantined and none was promoted. The current discovery snapshot contains 12 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, vendor product page, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Care setting: Not publicly available - checked 2026-11-12 - Exact FDA submission

    The exact FDA decision-summary packet limits use to "GE HealthCare 1.5T, 3.0T, and 7.0T MR systems" but states no hospital, outpatient, or other care setting; the earlier hospital and outpatient value was not supported by this source and was removed. Unknown does not mean unrestricted. Agent source review, not clinician sign-off.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-11-12 - Exact FDA submission

    The exact FDA decision-summary packet states no operator or interpreter group and no training requirement beyond the checked "Prescription Use (Part 21 CFR 801 Subpart D)" box; the earlier user-restriction value was not supported by this source and was removed. Training prerequisites and competency checks for the exact configuration require vendor confirmation; local onboarding should still cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation. Agent source review, not clinician sign-off.

11 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K252379: AIR Recon DL

    U.S. Food and Drug Administration - Published 2025-12-23 - Accessed 2026-09-04

    Scope: identity, productIdentity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Impact of Deep Learning Image Reconstruction Methods on MRI Throughput

    Radiology: Artificial Intelligence - Published 2024-03-20 - Accessed 2026-09-02

    Scope: evidenceSummary, evidenceStudy, evidenceMetrics, economicsObservation, implementationCapabilities

  8. GE HealthCare AIR Recon DL

    GE HealthCare - Accessed 2026-09-03

    Scope: integration, deployment, monitoring, productFamilyContext

  9. GE HealthCare: Product Security (portal and Cybersecurity Risk Management System)

    GE HealthCare - Accessed 2026-10-26

    Scope: security

  10. FDA K213717: AIR Recon DL

    U.S. Food and Drug Administration - Published 2022-06-08 - Accessed 2026-11-09

    Scope: purpose, modality, anatomy, evidenceSummary, input, output, limitations, clinicalUse, product_family

  11. FDA 510(k) decision material K252379: AIR Recon DL

    U.S. Food and Drug Administration - Published 2025-12-23 - Accessed 2026-11-09

    Scope: identity, productIdentity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary, product_family

Research history

  1. K252379 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260746

S-scan Open (100001800)

Esaote, S.p.A.

Authorized purpose: S-scan Open is an Esaote MR system for diagnostic image acquisition, reconstruction, display, and professional interpretation within the labeled scanner, coil, sequence, and anatomy scope.

Modality
MRI
Anatomy
Multi-region
Decision
2026-03-27
FDA-cleared K252838

MAGNETOM Sola; MAGNETOM Altea; MAGNETOM Sola Fit; MAGNETOM Viato.Mobile; MAGNETOM Vida; MAGNETOM Lumina; MAGNETOM Vida Fit; MAGNETOM Flow.Elite; MAGNETOM Flow.Neo; MAGNETOM Flow.Rise

Siemens Healthcare GmbH

Authorized purpose: The listed MAGNETOM 1.5T and 3T MRI systems produce cross-sectional images, spectroscopic images or spectra, and derived physical parameters of the head, body, and extremities for trained-physician interpretation and can support imaging during MR-compatible interventions.

Modality
MRI
Anatomy
Multi-region
Decision
2025-12-19
FDA-cleared K251822

MAGNETOM Free.Max; MAGNETOM Free.Star

Siemens Shenzhen Magnetic Resonance, Ltd.

Authorized purpose: MAGNETOM Free.Max and Free.Star with syngo MR XA80A are 0.55T MRI systems for broad imaging and compatible interventions; this release adds dentomaxillofacial coil and assist functions plus reconstruction and energy-mode updates.

Modality
MRI
Anatomy
Multi-region
Decision
2025-11-20

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history